ReviewInfection2026
Whipple's endocarditis and biologic response modifiers: a case-based review of an intricate host-pathogen interaction.
Review in Infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Whipple's disease is a rare and chronic multisystem infectious disorder caused by Tropheryma whipplei. Blood-culture negative infective endocarditis may complicate the course of classical Whipple's disease or appear as an isolated manifestation. The pathophysiology of this rare and complex disorder is still unclear, and the appropriate therapeutic management is debated. Recent reports have highlighted the role of biologic response modifiers in causing overt disease or in accelerating patient presentation by worsening pre-existing symptoms especially when administered in patients with isolated joint manifestations. In this clinical scenario, we describe the first reported case of classical Whipple's disease complicated with endocarditis in which patient symptoms were exacerbated by administration of IL-17 inhibitors. The patient presented with a history of long-standing fever and seronegative spondylarthritis and received a diagnosis of native aortic valve blood-culture negative infective endocarditis. Associated gastrointestinal symptoms prompted duodenal endoscopy with histology and molecular biology confirming the diagnosis. The following review provides valuable insights in the pathophysiology, diagnosis, treatment and long-term management of Whipple's disease and underlies how modern medicine and newer treatment options are shaping the host-pathogen interaction and presentation patterns of infectious diseases.
Indexed as
Identifiers
42234338What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.